ArticlePharmacoEconomics - open2022

Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden.

I van Oostrum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.